

# Nadine M Tung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7861814/publications.pdf>

Version: 2024-02-01

150  
papers

15,872  
citations

31902

53  
h-index

18075

120  
g-index

154  
all docs

154  
docs citations

154  
times ranked

17571  
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 523-533.	13.9	2,256
2	Association of Risk-Reducing Surgery in <i>BRCA1</i> or <i>BRCA2</i> Mutation Carriers With Cancer Risk and Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 967.	3.8	1,241
3	Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1145-1153.	0.8	860
4	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3764-3773.	3.2	733
5	Contralateral Breast Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2004, 22, 2328-2335.	0.8	595
6	Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>Journal of Clinical Oncology</i> , 2014, 32, 1547-1553.	0.8	523
7	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 134-147.	1.1	513
8	Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents. <i>Cancer Discovery</i> , 2012, 2, 366-375.	7.7	464
9	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1460-1468.	0.8	413
10	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	3.8	390
11	Frequency of mutations in individuals with breast cancer referred for <i>BRCA1</i> and <i>BRCA2</i> testing using next-generation sequencing with a 25-gene panel. <i>Cancer</i> , 2015, 121, 25-33.	2.0	372
12	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
13	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	0.8	318
14	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. <i>JAMA Oncology</i> , 2015, 1, 943.	3.4	294
15	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	9.4	289
16	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. <i>Journal of Clinical Oncology</i> , 2020, 38, 4274-4282.	0.8	276
17	Estrogen Receptor Status in <i>BRCA1</i> - and <i>BRCA2</i> -Related Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2029-2034.	3.2	270
18	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265

#	ARTICLE	IF	CITATIONS
19	Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 581-588.	12.5	258
20	Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. <i>International Journal of Cancer</i> , 2006, 118, 2281-2284.	2.3	246
21	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	1.5	244
22	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	1.1	224
23	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	9.4	221
24	Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 2080-2106.	0.8	178
25	Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	160
26	BRCA1/2 testing: therapeutic implications for breast cancer management. <i>British Journal of Cancer</i> , 2018, 119, 141-152.	2.9	142
27	Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer. <i>Nature Cancer</i> , 2021, 2, 66-82.	5.7	126
28	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	9.4	125
29	Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. <i>JAMA Oncology</i> , 2018, 4, 1059.	3.4	121
30	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	9.4	120
31	Evolutionary Pathways in BRCA1-Associated Breast Tumors. <i>Cancer Discovery</i> , 2012, 2, 503-511.	7.7	116
32	Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. <i>JAMA Oncology</i> , 2015, 1, 306.	3.4	107
33	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. <i>British Journal of Cancer</i> , 2019, 121, 15-21.	2.9	101
34	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. <i>Breast Cancer Research</i> , 2014, 16, 3419.	2.2	97
35	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016, 7, 11375.	5.8	93
36	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. <i>Nature Communications</i> , 2019, 10, 1741.	5.8	90

#	ARTICLE	IF	CITATIONS
37	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
38	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
39	TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline <i>BRCA</i> Carriers With HER2-Negative Breast Cancer (the INFORM trial). <i>Journal of Clinical Oncology</i> , 2020, 38, 1539-1548.	0.8	88
40	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	1.1	82
41	Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. <i>Breast Cancer Research</i> , 2010, 12, R12.	2.2	81
42	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	5.8	78
43	Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 366-371.	0.7	76
44	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
45	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	1.3	75
46	Patterns of recurrence and metastasis in <i>BRCA1/BRCA2</i> -associated breast cancers. <i>Cancer</i> , 2020, 126, 271-280.	2.0	74
47	Clinical outcome of triple negative breast cancer in <i>BRCA1</i> mutation carriers and noncarriers. <i>Cancer</i> , 2011, 117, 3093-3100.	2.0	70
48	Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma. <i>Cancer</i> , 2018, 124, 3520-3527.	2.0	66
49	Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2018, 150, 85-91.	0.6	65
50	Altered Proliferation and Differentiation Properties of Primary Mammary Epithelial Cells from BRCA1 Mutation Carriers. <i>Cancer Research</i> , 2009, 69, 1273-1278.	0.4	63
51	When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?. <i>Journal of Oncology Practice</i> , 2019, 15, 465-473.	2.5	63
52	Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 124, 195-203.	1.1	58
53	Factors influencing ovulation and the risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Cancer</i> , 2015, 137, 1136-1146.	2.3	56
54	Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 365-373.	1.1	55

#	ARTICLE	IF	CITATIONS
55	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.4	54
56	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	0.8	52
57	Li-Fraumeni syndrome: not a straightforward diagnosis anymore—the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. <i>Breast Cancer Research</i> , 2019, 21, 107.	2.2	51
58	Characterization of the Cancer Spectrum in Men With Germline <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. <i>JAMA Oncology</i> , 2020, 6, 1218.	3.4	48
59	Inheritance of deleterious mutations at both <i>BRCA1</i> and <i>BRCA2</i> in an international sample of 32,295 women. <i>Breast Cancer Research</i> , 2016, 18, 112.	2.2	42
60	PARP inhibition in breast cancer: progress made and future hopes. <i>Npj Breast Cancer</i> , 2022, 8, 47.	2.3	42
61	Prevalence and predictors of loss of wild type <i>BRCA1</i> in estrogen receptor positive and negative <i>BRCA1</i> -associated breast cancers. <i>Breast Cancer Research</i> , 2010, 12, R95.	2.2	41
62	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
63	Treatment of infertility does not increase the risk of ovarian cancer among women with a <i>BRCA1</i> or <i>BRCA2</i> mutation. <i>Fertility and Sterility</i> , 2016, 105, 781-785.	0.5	38
64	Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline <i>BRCA</i> Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 2959-2961.	0.8	34
65	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	0.6	32
66	Should all <i>BRCA1</i> mutation carriers with stage I breast cancer receive chemotherapy?. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 273-279.	1.1	31
67	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	2.2	31
68	Prevalence and predictors of androgen receptor and programmed death-ligand 1 in <i>BRCA1</i> -associated and sporadic triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2016, 2, 16002.	2.3	31
69	Height and Body Mass Index as Modifiers of Breast Cancer Risk in <i>BRCA1/2</i> Mutation Carriers: A Mendelian Randomization Study. <i>Journal of the National Cancer Institute</i> , 2019, 111, 350-364.	3.0	30
70	Breast cancer screening in the era of density notification legislation: summary of 2014 Massachusetts experience and suggestion of an evidence-based management algorithm by multi-disciplinary expert panel. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 455-464.	1.1	28
71	Management of Women With <i>BRCA</i> Mutations. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2211.	3.8	27
72	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	2.2	26

#	ARTICLE	IF	CITATIONS
73	<i>BRCA1</i> and <i>BRCA2</i> pathogenic sequence variants in women of African origin or ancestry. <i>Human Mutation</i> , 2019, 40, 1781-1796.	1.1	26
74	Tumor-Infiltrating Lymphocytes and Response to Platinum in Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 969-971.	0.8	25
75	Oestrogen receptor status and survival in women with <i>BRCA2</i> -associated breast cancer. <i>British Journal of Cancer</i> , 2019, 120, 398-403.	2.9	25
76	The incidence of leukaemia in women with <i>BRCA1</i> and <i>BRCA2</i> mutations: an International Prospective Cohort Study. <i>British Journal of Cancer</i> , 2016, 114, 1160-1164.	2.9	24
77	Retinoblastoma protein expression and its predictors in triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 19.	2.3	23
78	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
79	The impact of oophorectomy on survival after breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1507-1507.	0.8	22
80	Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 512-512.	0.8	22
81	Outcome of triple negative breast cancer: comparison of sporadic and <i>BRCA1</i> -associated cancers. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 175-182.	1.1	21
82	Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. <i>Clinical Breast Cancer</i> , 2020, 20, 145-151.e2.	1.1	21
83	Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 2704-2710.	3.2	21
84	Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years. <i>Cancer</i> , 2021, 127, 828-833.	2.0	20
85	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>British Journal of Cancer</i> , 2019, 121, 180-192.	2.9	19
86	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). <i>Breast Cancer Research and Treatment</i> , 2021, 189, 103-110.	1.1	19
87	Immediate breast reconstruction following mastectomy in pregnant women with breast cancer. <i>Journal of Surgical Oncology</i> , 2016, 114, 140-143.	0.8	18
88	Association of breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	1.1	18
89	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 63.	2.3	18
90	Chek2 DNA Damage Response Pathway and Inherited Breast Cancer Risk. <i>Journal of Clinical Oncology</i> , 2011, 29, 3813-3815.	0.8	16

#	ARTICLE	IF	CITATIONS
91	Managing hereditary breast cancer risk in women with and without ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 205-214.	0.6	16
92	Patient perspectives on chemotherapy de-escalation in breast cancer. <i>Cancer Medicine</i> , 2021, 10, 3288-3298.	1.3	16
93	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	1.1	16
94	Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 641-651.	1.1	16
95	What Is the Optimal Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2013, 31, 1391-1397.	0.8	13
96	Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2019, 125, 2488-2496.	2.0	13
97	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2189-2192.	0.8	12
98	Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 443-449.	1.1	12
99	Survival from breast cancer in women with a BRCA2 mutation by treatment. <i>British Journal of Cancer</i> , 2021, 124, 1524-1532.	2.9	12
100	Pathologic Features and Immunophenotype of Estrogen Receptor-positive Breast Cancers in BRCA1 Mutation Carriers. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1483-1488.	2.1	11
101	Frequency of Triple-Negative Breast Cancer in BRCA1 Mutation Carriers: Comparison Between Common Ashkenazi Jewish and Other Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 4447-4448.	0.8	10
102	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 421-426.	1.1	10
103	Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2020, 159, 820-826.	0.6	10
104	Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test. <i>Journal of Clinical Oncology</i> , 2021, 39, 3415-3418.	0.8	9
105	Factors associated with use of hormone therapy after preventive oophorectomy in BRCA mutation carriers. <i>Menopause</i> , 2020, 27, 1396-1402.	0.8	8
106	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	1.1	8
107	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study. <i>Genetics in Medicine</i> , 2022, 24, 564-575.	1.1	8
108	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Gynecologic Oncology</i> , 2022, 164, 514-521.	0.6	8



#	ARTICLE	IF	CITATIONS
109	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8
110	Challenges in Interpreting Germline Mutations in <i>BARD1</i> and <i>ATM</i> in Breast and Ovarian Cancer Patients. <i>Breast Journal</i> , 2017, 23, 461-464.	0.4	7
111	Evaluation of <i>TP53</i> Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic <i>TP53</i> Variants. <i>JCO Precision Oncology</i> , 2021, 5, 1677-1686.	1.5	7
112	Weight Gain and the Risk of Ovarian Cancer in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2038-2043.	1.1	6
113	Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 1009-1009.	0.8	6
114	Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?. <i>Menopause</i> , 2020, 27, 156-161.	0.8	5
115	Comparison of up-front cash cards and checks as incentives for participation in a clinician survey: a study within a trial. <i>BMC Medical Research Methodology</i> , 2020, 20, 210.	1.4	5
116	Breast cancer risk after age 60 among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 515-523.	1.1	5
117	A Pre-Test Post-Test Trial of a Breast Cancer Risk Report for Women in Their 40s. <i>American Journal of Preventive Medicine</i> , 2020, 59, 343-354.	1.6	4
118	Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 825-830.	1.2	4
119	Adjuvant palbociclib (P) plus endocrine therapy (ET) for hormone receptor positive (HR+) breast cancer: A phase II feasibility study.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS654-TPS654.	0.8	4
120	Abstract P2-14-17: A phase 1b study of PVX-410 vaccine in combination with pembrolizumab in metastatic triple negative breast cancer (mTNBC). <i>Cancer Research</i> , 2022, 82, P2-14-17-P2-14-17.	0.4	4
121	Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations. <i>Breast Journal</i> , 2019, 25, 575-577.	0.4	3
122	Challenges in Interpreting <i>TP53</i> Pathogenic Variants With a Low Minor Allele Frequency in Germline Genetic Testing: A Case Report of a Patient With Mosaic Li-Fraumeni Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 91-95.	1.5	3
123	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 411-423.	1.1	3
124	Bilateral Oophorectomy and the Risk of Breast Cancer in <i>BRCA1</i> Mutation Carriers: A Reappraisal. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1351-1358.	1.1	3
125	Reply to S. Takamizawa et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 2700-2701.	0.8	2
126	Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. <i>Journal of General Internal Medicine</i> , 2021, , 1.	1.3	2



#	ARTICLE	IF	CITATIONS
127	Prevalence and predictors of androgen receptor (AR) and programmed death-ligand 1 (PD-L1) expression in BRCA1-associated and sporadic triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1005-1005.	0.8	2
128	Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. Breast Journal, 2020, 26, 1506-1512.	0.4	1
129	Limitations of direct-to-consumer (DTC) genetic testing for hereditary breast and ovarian cancer.. Journal of Clinical Oncology, 2021, 39, 10515-10515.	0.8	1
130	A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.. Journal of Clinical Oncology, 2021, 39, TPS595-TPS595.	0.8	1
131	Analysis of real-world (RW) data for metastatic breast cancer (mBC) patients (pts) with somatic <i>BRCA1/2</i> or other homologous recombination (HR)-pathway gene mutations (mut) treated with PARP inhibitors (PARPi).. Journal of Clinical Oncology, 2021, 39, 10512-10512.	0.8	1
132	860€...Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer. , 2020, , .		1
133	Clinical impact of multi-gene panel testing for hereditary breast and ovarian cancer risk assessment.. Journal of Clinical Oncology, 2015, 33, 1513-1513.	0.8	1
134	TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)“Evaluating the homologous recombination deficiency (HRD) biomarker.. Journal of Clinical Oncology, 2014, 32, TPS1145-TPS1145.	0.8	1
135	Q and A: A New Standard of Care for Germline <i>BRCA1</i> and/or <i>BRCA2</i> Mutation Carriers With Early-Stage Breast Cancer. JCO Oncology Practice, 2022, 18, 427-429.	1.4	1
136	Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with <i>BRCA1/2</i> -associated, hormone receptor-positive, HER2-negative metastatic breast cancer. Cancer Research, 2022, 82, OT2-18-01-OT2-18-01.	0.4	1
137	Abstract P2-14-18: A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer. Cancer Research, 2022, 82, P2-14-18-P2-14-18.	0.4	1
138	Longitudinal circulating tumor DNA (ctDNA) whole-exome sequencing (WES) in the phase Ib/II trial of palbociclib and bazedoxifene reveals genomic dynamics and clonal evolution with the acquisition of treatment resistance in hormone receptor-positive, HER2-negative (HR+ HER2-), advanced breast cancer (ABC).. Journal of Clinical Oncology, 2022, 40, 1058-1058.	0.8	1
139	Reply to K. Zaman et al. Journal of Clinical Oncology, 2013, 31, 3441-3441.	0.8	0
140	Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study. Hereditary Cancer in Clinical Practice, 2020, 18, 13.	0.6	0
141	Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.. Journal of Clinical Oncology, 2021, 39, 10531-10531.	0.8	0
142	Immediate tissue expander breast reconstruction following mastectomy in pregnancy-associated breast cancer.. Journal of Clinical Oncology, 2013, 31, 1133-1133.	0.8	0
143	Sentinel lymph node biopsy (SNB) in pregnancy-associated breast cancer (PABC).. Journal of Clinical Oncology, 2013, 31, 1117-1117.	0.8	0
144	A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with metastatic, human epidermal growth factor receptor 2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS668-TPS668.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Predisposing germline mutations in high grade ER+HER2- breast cancer (BC) patients diagnosed (Dx).. Journal of Clinical Oncology, 2015, 33, 1503-1503.	0.8	0
146	Perceptions of genetic testing among patients undergoing genetic counseling.. Journal of Clinical Oncology, 2016, 34, e13107-e13107.	0.8	0
147	Distant recurrences in triple negative breast cancer (TNBC) according to androgen receptor (AR) status.. Journal of Clinical Oncology, 2016, 34, 1085-1085.	0.8	0
148	The risks of breast and ovarian cancer associated with the Ashkenazi Jewish founder allele <sc><i>BRCA2</i> 6174delT</sc>. Clinical Genetics, 2022, 101, 317-323.	1.0	0
149	Abstract P3-18-05: Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial. Cancer Research, 2022, 82, P3-18-05-P3-18-05.	0.4	0
150	Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 525-525.	0.8	0